A world leader in molecular cancer diagnostics, Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatment within reach of cancer patients. Leveraging its cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatment.  Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies, the NIH, NCI, and FDA to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

Web: www.agendia.com/